Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 11/20 | 0.59 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.59 |
| ▸ | RXRA | P19793 | 9/20 | 0.59 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1679296 | 0.81 | NR1H2 (0.52) | NR1H2NR1H3RXRAMAOBMAOA | |
| SCHEMBL1679402 | 0.80 | NR1H2 (0.51) | NR1H2NR1H3RXRAMAOBMAOA | |
| SCHEMBL1678568 | 0.79 | NR1H2 (0.50) | NR1H2NR1H3RXRAMAOBMAOA | |
| SCHEMBL1679387 | 0.79 | NR1H2 (0.48) | NR1H2NR1H3RXRAMAOBMAOA | |
| SCHEMBL1679104 | 0.78 | NR1H2 (0.49) | NR1H2NR1H3RXRAGAA | |
| SCHEMBL1679540 | 0.78 | NR1H2 (0.51) | NR1H2NR1H3RXRASRD5A2GAA | |
| SCHEMBL5062321 | 0.78 | NR1H3 (0.41) | NR1H2NR1H3RXRAMAOBMAOA | |
| SCHEMBL1679493 | 0.78 | NR1H2 (0.44) | NR1H2NR1H3RXRAHTR2A | |
| SCHEMBL1679491 | 0.78 | NR1H2 (0.44) | NR1H2NR1H3RXRAHTR2A | |
| SCHEMBL1678612 | 0.77 | NR1H2 (0.49) | NR1H2NR1H3RXRAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255111-A1 | Tissue Factor Production Inhibitor | SANKYO COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| EP-1764075-A1 | TISSUE FACTOR PRODUCTION INHIBITOR | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255111-A1 | Tissue Factor Production Inhibitor | PTAFR, PLAT, TFPI | NR1H2 7/4885NR1H3 6/4885RXRA 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.